The effect of fatty diacid acylation of human PYY


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 10 2021
Historique:
received: 15 07 2021
accepted: 13 10 2021
entrez: 28 10 2021
pubmed: 29 10 2021
medline: 27 1 2022
Statut: epublish

Résumé

Peptides are notoriously known to display very short in vivo half-lives often measured in minutes which in many cases greatly reduces or eliminates sufficient in vivo efficacy. To obtain long half-lives allowing for up to once-weekly dosing regimen, fatty acid acylation (lipidation) have been used to non-covalently associate the peptide to serum albumin thus serving as a circulating depot. This approach is generally considered in the scientific and patent community as a standard approach to protract almost any given peptide. However, it is not trivial to prolong the half-life of peptides by lipidation and still maintain high potency and good formulation properties. Here we show that attaching a fatty acid to the obesity-drug relevant peptide PYY

Identifiants

pubmed: 34707178
doi: 10.1038/s41598-021-00654-3
pii: 10.1038/s41598-021-00654-3
pmc: PMC8551270
doi:

Substances chimiques

Anti-Obesity Agents 0
Drug Combinations 0
Fatty Acids 0
Oligopeptides 0
Receptors, Neuropeptide Y 0
Peptide YY 106388-42-5
Liraglutide 839I73S42A

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21179

Informations de copyright

© 2021. The Author(s).

Références

Endocrinology. 2011 Dec;152(12):4630-40
pubmed: 21952244
Mol Metab. 2018 Dec;18:3-14
pubmed: 30473097
Biochemistry. 2013 Nov 12;52(45):7987-98
pubmed: 24111902
Mol Pharmacol. 2018 Apr;93(4):323-334
pubmed: 29367257
Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R1195-201
pubmed: 19710388
Int J Pept Protein Res. 1990 Dec;36(6):522-30
pubmed: 2090644
J Med Chem. 2018 Dec 13;61(23):10519-10530
pubmed: 30399314
Bioconjug Chem. 2013 Dec 18;24(12):2015-24
pubmed: 24251972
Drug Metab Pharmacokinet. 2016 Feb;31(1):73-81
pubmed: 26776246
Physiol Rep. 2015 Jul;3(7):
pubmed: 26197931
Peptides. 2018 Feb;100:269-274
pubmed: 29412828
J Biol Chem. 1967 Jan 25;242(2):173-81
pubmed: 6016603
J Pharmacol Exp Ther. 2007 Nov;323(2):692-700
pubmed: 17671099
Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):163-172
pubmed: 33386550
Biochemistry. 1993 Aug 24;32(33):8654-60
pubmed: 8357807
Cell Metab. 2019 Apr 2;29(4):837-843.e5
pubmed: 30773465
BMC Biotechnol. 2015 Jun 27;15:61
pubmed: 26116580
Biochemistry. 2006 Jul 11;45(27):8350-7
pubmed: 16819834
J Med Chem. 2020 Sep 10;63(17):9660-9671
pubmed: 32844654
Gastroenterology. 1985 Nov;89(5):1070-7
pubmed: 3840109
Bioorg Med Chem Lett. 2007 Apr 1;17(7):1916-9
pubmed: 17292607
Eur J Neurosci. 2010 Sep;32(5):826-39
pubmed: 20646064
Pharmacol Ther. 2016 May;161:22-39
pubmed: 27016466
Angew Chem Int Ed Engl. 2015 Jun 15;54(25):7446-9
pubmed: 25924821
Can J Comp Med Vet Sci. 1963 Nov;27(11):269-73
pubmed: 17649473
Endocrinology. 2005 Dec;146(12):5120-7
pubmed: 16150917
Eur J Pharm Sci. 2017 Jun 15;104:31-41
pubmed: 28323117
Cell Metab. 2011 Nov 2;14(5):700-6
pubmed: 22000927
Diabetes Obes Metab. 2021 Jul;23(7):1471-1483
pubmed: 33606914
Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1248-56
pubmed: 24735885
J Med Chem. 2000 May 4;43(9):1664-9
pubmed: 10794683
Biochem Pharmacol. 2018 Dec;158:95-102
pubmed: 30292757
J Clin Endocrinol Metab. 1986 Oct;63(4):803-7
pubmed: 3755728
Peptides. 1989 Jul-Aug;10(4):797-803
pubmed: 2587421
Nature. 2002 Aug 8;418(6898):650-4
pubmed: 12167864
J Med Chem. 2007 Nov 29;50(24):6126-32
pubmed: 17975905
Gastroenterology. 2005 Nov;129(5):1430-6
pubmed: 16285944
N Engl J Med. 2003 Sep 4;349(10):941-8
pubmed: 12954742
Pharm Res. 2004 Aug;21(8):1498-504
pubmed: 15359587
J Pharm Sci. 1996 Mar;85(3):304-8
pubmed: 8699334
Mol Pharm. 2015 Feb 2;12(2):411-9
pubmed: 25569709
J Med Chem. 2015 Sep 24;58(18):7370-80
pubmed: 26308095
Pharm Res. 2012 Aug;29(8):2104-14
pubmed: 22485010
Peptides. 2016 Apr;78:59-67
pubmed: 26774588
ChemMedChem. 2014 Nov;9(11):2463-74
pubmed: 25156249

Auteurs

Søren Østergaard (S)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark. sq@novonordisk.com.

Johan F Paulsson (JF)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Jacob Kofoed (J)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Franziska Zosel (F)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Jørgen Olsen (J)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Claus Bekker Jeppesen (CB)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Jane Spetzler (J)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Lars Ynddal (L)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.
Gubra Aps, Hørsholm Kongevej 11B, 2970, Hørsholm, Denmark.

Luise Gram Schleiss (LG)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Berit Østergaard Christoffersen (BØ)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Kirsten Raun (K)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Ulrich Sensfuss (U)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.
STipe Therapeutics, Copenhagen, Denmark.

Flemming Seier Nielsen (FS)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Rasmus Jørgensen (R)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.
CitoKi Pharma, Værløse, Denmark.

Birgitte S Wulff (BS)

Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH